Last reviewed · How we verify
Zymar®
Zymar®, marketed by Laboratorios Sophia S.A de C.V., is an established product in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence and the protection afforded by its patent, which helps maintain its competitive edge. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Zymar® |
|---|---|
| Also known as | Gatifloxacin, gatifloxacin |
| Sponsor | Laboratorios Sophia S.A de C.V. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (PHASE2)
- A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis (PHASE4)
- Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zymar® CI brief — competitive landscape report
- Zymar® updates RSS · CI watch RSS
- Laboratorios Sophia S.A de C.V. portfolio CI